{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:56Z","timestamp":1786119296519,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1097\/fjc.0b013e3181a59abc","type":"journal-article","created":{"date-parts":[[2009,6,12]],"date-time":"2009-06-12T07:16:47Z","timestamp":1244791007000},"page":"440-445","source":"Crossref","is-referenced-by-count":9,"title":["Differences Among Low-Molecular-Weight Heparins: Evidence in Patients With Acute Coronary Syndromes"],"prefix":"10.1097","volume":"53","author":[{"given":"Jose C","family":"Nicolau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210208","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2007.02.013","article-title":"American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina\/Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC\/AHA 2007 guidelines for the management of patients with unstable angina\/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina\/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.","volume":"50","author":"Anderson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R2-3-20210208","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jama.292.1.89","article-title":"Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.","volume":"292","author":"Petersen","year":"2004","journal-title":"JAMA"},{"key":"R3-3-20210208","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/eurheartj\/ehm224","article-title":"Efficacy and safety of the low-molecular-weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.","volume":"28","author":"Murphy","year":"2007","journal-title":"Eur Heart J"},{"key":"R4-3-20210208","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.96.1.61","article-title":"Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).","volume":"96","author":"Klein","year":"1997","journal-title":"Circulation"},{"key":"R5-3-20210208","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1053\/euhj.1999.1879","article-title":"I.S. Study Group. Comparison of two treatment durations (6 days and 14 days) of a low-molecular-weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).","volume":"20","author":"The","year":"1999","journal-title":"Eur Heart J"},{"key":"R6-3-20210208","first-page":"45","article-title":"SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"key":"R7-3-20210208","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJMoa052711","article-title":"STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.","volume":"355","author":"Montalescot","year":"2006","journal-title":"N Engl J Med"},{"key":"R9-3-20210208","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1161\/CIRCULATIONAHA.105.573550","article-title":"Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.","volume":"112","author":"Eikelboom","year":"2005","journal-title":"Circulation"},{"key":"R10-3-20210208","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1161\/CIRCULATIONAHA.105.595397","article-title":"Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.","volume":"112","author":"Sabatine","year":"2005","journal-title":"Circulation"},{"key":"R11-3-20210208","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0735-1097(03)01040-4","article-title":"TETAMI Investigators. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.","volume":"42","author":"Cohen","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R12-3-20210208","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0002-9149(03)00020-1","article-title":"Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction.","volume":"91","author":"Theroux","year":"2003","journal-title":"Am J Cardiol"},{"key":"R13-3-20210208","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jama.293.4.427","article-title":"CREATE Trial Group Investigators. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation.","volume":"293","author":"Yusuf","year":"2005","journal-title":"JAMA"},{"key":"R14-3-20210208","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0195-668X(03)00006-X","article-title":"Low-molecular-weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.","volume":"24","author":"Wallentin","year":"2003","journal-title":"Eur Heart J"},{"key":"R16-3-20210208","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","article-title":"ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.","volume":"354","author":"Antman","year":"2006","journal-title":"N Engl J Med"},{"key":"R17-3-20210208","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.107.188209","article-title":"2004 Writing Committee Members. 2007 Focused Update of the ACC\/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC\/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee.","volume":"117","author":"Antman","year":"2008","journal-title":"Circulation"},{"key":"R18-3-20210208","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1993.03510140024010","article-title":"From the Food and Drug Administration.","volume":"270","author":"Nightingale","year":"1993","journal-title":"JAMA"},{"key":"R19-3-20210208","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0002-8703(00)90090-5","article-title":"Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum.","volume":"139","author":"Antman","year":"2000","journal-title":"Am Heart J"},{"key":"R20-3-20210208","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2165\/00003088-200342120-00003","article-title":"Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice.","volume":"42","author":"Fareed","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"R21-3-20210208","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/107602960501100401","article-title":"Generic low-molecular-weight heparins: a significant dilemma.","volume":"11","author":"Fareed","year":"2005","journal-title":"Clin Appl Thromb Hemost"},{"key":"R22-3-20210208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2004.09.003","article-title":"Unfractionated heparin, low-molecular-weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use.","volume":"19","author":"Bick","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"key":"R23-3-20210208","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.hoc.2004.09.005","article-title":"Development of generic low-molecular-weight heparins: a perspective.","volume":"19","author":"Fareed","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"issue":"Suppl 1","key":"R24-3-20210208","first-page":"77","article-title":"Are the available low-molecular-weight heparin preparations the same?","volume":"22","author":"Fareed","year":"1996","journal-title":"Semin Thromb Hemost"},{"key":"R25-3-20210208","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00001721-199601000-00003","article-title":"Inhibition of thrombin generation by heparin and LMW heparins: a comparison of chromogenic and clotting methods.","volume":"7","author":"Houbouyan","year":"1996","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R26-3-20210208","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2141.1992.tb06437.x","article-title":"Inhibition of thrombin generation by heparin and low-molecular-weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4).","volume":"82","author":"Padilla","year":"1992","journal-title":"Br J Haematol"},{"key":"R27-3-20210208","first-page":"203","article-title":"The haemorrhagic effect of low-molecular-weight heparins, dermatan sulphate and hirudin.","volume":"25","author":"Matthiasson","year":"1995","journal-title":"Haemostasis"},{"key":"R28-3-20210208","first-page":"124","article-title":"Prevention of experimental venous thrombosis in rabbits with different low-molecular-weight heparins, dermatan sulphate and hirudin.","volume":"25","author":"Matthiasson","year":"1995","journal-title":"Haemostasis"},{"key":"R29-3-20210208","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1749-6632.1989.tb22515.x","article-title":"Biochemical and pharmacologic inequivalence of low-molecular-weight heparins.","volume":"556","author":"Fareed","year":"1989","journal-title":"Ann N Y Acad Sci"},{"key":"R30-3-20210208","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/s-0038-1642434","article-title":"Ex-vivo and in-vitro evidence that low-molecular-weight heparins exhibit less binding to plasma proteins than unfractionated heparin.","volume":"71","author":"Young","year":"1994","journal-title":"Thromb Haemost"},{"key":"R31-3-20210208","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1055\/s-0038-1653833","article-title":"Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).","volume":"73","author":"Collignon","year":"1995","journal-title":"Thromb Haemost"},{"key":"R32-3-20210208","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0002-9149(03)00105-X","article-title":"ARMADA Investigators. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).","volume":"91","author":"Montalescot","year":"2003","journal-title":"Am J Cardiol"},{"key":"R33-3-20210208","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/01.CIR.98.4.294","article-title":"Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial.","volume":"98","author":"Montalescot","year":"1998","journal-title":"Circulation"},{"key":"R34-3-20210208","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0735-1097(00)00695-1","article-title":"Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.","volume":"36","author":"Montalescot","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R35-3-20210208","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/eurheartj\/ehi104","article-title":"Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy.","volume":"26","author":"Ray","year":"2005","journal-title":"Eur Heart J"},{"key":"R36-3-20210208","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0002-8703(03)00179-0","article-title":"Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial.","volume":"146","author":"Michalis","year":"2003","journal-title":"Am Heart J"},{"key":"R37-3-20210208","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ahj.2004.09.028","article-title":"Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months.","volume":"150","author":"Katsouras","year":"2005","journal-title":"Am Heart J"},{"key":"R38-3-20210208","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1076029606291434","article-title":"Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.","volume":"12","author":"Maddineni","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"R40-3-20210208","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrd2307","article-title":"The FDAs assessment of follow-on protein products: a historical perspective.","volume":"6","author":"Woodcock","year":"2007","journal-title":"Nat Rev Drug Discov"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FJC.0b013e3181a59abc","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:55:12Z","timestamp":1786038912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005344-200906000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/fjc.0b013e3181a59abc","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}